Ernest Camp to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Ernest Camp has written about Drug Resistance, Neoplasm.
Connection Strength
0.757
-
Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res. 2005 Jan 01; 11(1):397-405.
Score: 0.207
-
Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer. J Am Coll Surg. 2004 Aug; 199(2):249-58.
Score: 0.201
-
SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression. Mol Cancer Ther. 2014 Nov; 13(11):2713-26.
Score: 0.101
-
Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther. 2014 May; 21(5):181-7.
Score: 0.099
-
Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr; 20(4):222-8.
Score: 0.091
-
Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4147-53.
Score: 0.058